Physician profile
Chen Chen
NPI 1114380631
$6,797.72
in general payments reported to CMS, 2019-2025
18 companies · $3,746 in 2025
The $3,746 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $72.65 · 2021: $71.60 · 2022: $264 · 2023: $1,196 · 2024: $1,448 · 2025: $3,746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,378 · Education: $11.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,377.78 |
| Education | $11.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,091.62 | 2022-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $706.99 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $695.96 | 2023-2025 | Tremfya, Stelara |
| Arcutis Biotherapeutics, INC. | $622.42 | 2023-2025 | Zoryve |
| Amgen INC. | $597.61 | 2023-2025 | Otezla, Otezla, Amjevita |
| Abbvie INC. | $581.94 | 2020-2025 | Skyrizi, Rinvoq |
| Galderma Laboratories, L.P. | $556.92 | 2024-2025 | Nemluvio |
| Lilly USA, LLC | $552.84 | 2024-2025 | Ebglyss, Taltz |
| Genzyme Corporation | $292.05 | 2022-2025 | |
| Ucb, INC. | $207.34 | 2024-2025 | Bimzelx |
| Leo Pharma INC. | $202.15 | 2022-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $194.20 | 2022-2025 | Sotyktu |
| Organon LLC | $181.31 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $85.37 | 2024-2025 | |
| Dermavant Sciences, INC. | $84.90 | 2023-2024 | Vtama |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $72.30 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $56.39 | 2023-2024 | |
| Cipher Pharmaceuticals US LLC | $15.41 | 2025 | Natroba, Spinosad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chen Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.